← Search & browse all drugs

magaldrate and antiflatulents

A02AF01

Forms & Strengths

Oral Suspension: Magaldrate 400-540 mg / Simethicone 20-40 mg per 5 mL
Chewable Tablets: Magaldrate 480 mg / Simethicone 20 mg

Adult Dosing

5 to 10 mL (or 1 to 2 tablets) between meals and at bedtime, or as needed for symptoms
Maximum daily dose: Follow package labeling or clinician guidance, typically not to exceed QID dosing

Pediatric Dosing

Safety and efficacy in pediatric patients under 12 years are not well established
Use in children is generally discouraged unless specifically directed by a pediatrician

Indications

Symptomatic relief of hyperacidity associated with peptic ulcer disease, gastritis, and esophagitis
Relief of symptoms associated with gas, including flatulence, bloating, and postprandial discomfort

Mechanism of Action

Magaldrate is a hydromerate of magnesium and aluminumates that rapidly neutralizes gastric hydrochloric acid
Simethicone is a surface-active antiflatulent agent that coalesces gas bubbles in the gastrointestinal tract to facilitate elimination

Contraindications

Hypersensitivity to aluminum or magnesium salts, or any component of the formulation
Severe renal impairment or failure due to risk of aluminum and magnesium accumulation and toxicity
Magnesium-induced laxative effect worsening severe diarrhea or bowel obstruction

Adverse Reactions

Constipation (primarily due to aluminum)
Diarrhea (primarily due to magnesium)
Hypermagnesemia in patients with renal dysfunction
Hypophosphatemia with prolonged use of aluminum-containing antacids

Drug Interactions

Decreases absorption of concurrently administered oral medications such as tetracyclines, fluoroquinolones, iron, and digoxin via chelation or increased gastric pH
Separate administration of interacting drugs by at least 2 hours before or after magaldrate

Curated Content: Needs Vetting Before Put to Clinical Use